Purpose <p>Cancer-related cognitive impairment (CRCI) is a prevalent comorbidity among breast cancer survivors, yet evidence supporting the efficacy of adaptive cognitive training remains limited. This pilot study seeks to examine participants’ adherence and preliminary effect of tablet-based cognitive training as an intervention for CRCI and apply eye tracking technology as an innovative approach to evaluate cognitive training outcomes.</p> Methods <p>Fifty-two eligible participants were randomly assigned to either the biofeedback therapy group (BF) or the combined biofeedback therapy and cognitive training group (BF + COG). Participants completed a 30-session intervention lasting 6&#xa0;weeks and eye tracking assessments at two timepoints: baseline and immediately after the intervention completion.</p> Results <p>Retention rates were 68% in the BF group and 70.4% in the BF + COG group. At the 6-week follow-up, the BF + COG group demonstrated significantly improved fixation stability. Under non-interfering conditions, they maintained fixation 307.76&#xa0;ms longer (<i>p</i> = 0.022,&#xa0;Cohen’s <i>d</i> = 0.307) and had a 32.4% reduction in saccadic distance (<i>p</i> = 0.019, Cohen’s <i>d</i> = -0.677) compared to BF. This advantage persisted under interference conditions with a 28.2% shorter saccadic distance (<i>p</i> = 0.034, Cohen’s <i>d</i> = -0.579). While within-group changes were not significant, the BF+COG group consistently showed reduced saccade distances across conditions, whereas the BF group exhibited increases.</p> Conclusion <p>Adaptive cognitive training may enhance attentional engagement and inhibitory control in breast cancer survivors. Large-scale study is needed to confirm these effects and refine eye-tracking applications for CRCI assessment.</p> Implications for Cancer Survivors <p>Tablet-based cognitive training targeting cognitive control&#xa0;with adaptive difficulty levels may ameliorate CRCI among breast cancer survivors.</p>

错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

Pilot randomized study of adaptive cognitive training’s effect on breast cancer survivors assessed through eye tracking

  • Yuxin Huang,
  • Ze Yu,
  • Youyang Wang,
  • Qun Liu,
  • Kuan Zhao,
  • Wei Feng

摘要

Purpose

Cancer-related cognitive impairment (CRCI) is a prevalent comorbidity among breast cancer survivors, yet evidence supporting the efficacy of adaptive cognitive training remains limited. This pilot study seeks to examine participants’ adherence and preliminary effect of tablet-based cognitive training as an intervention for CRCI and apply eye tracking technology as an innovative approach to evaluate cognitive training outcomes.

Methods

Fifty-two eligible participants were randomly assigned to either the biofeedback therapy group (BF) or the combined biofeedback therapy and cognitive training group (BF + COG). Participants completed a 30-session intervention lasting 6 weeks and eye tracking assessments at two timepoints: baseline and immediately after the intervention completion.

Results

Retention rates were 68% in the BF group and 70.4% in the BF + COG group. At the 6-week follow-up, the BF + COG group demonstrated significantly improved fixation stability. Under non-interfering conditions, they maintained fixation 307.76 ms longer (p = 0.022, Cohen’s d = 0.307) and had a 32.4% reduction in saccadic distance (p = 0.019, Cohen’s d = -0.677) compared to BF. This advantage persisted under interference conditions with a 28.2% shorter saccadic distance (p = 0.034, Cohen’s d = -0.579). While within-group changes were not significant, the BF+COG group consistently showed reduced saccade distances across conditions, whereas the BF group exhibited increases.

Conclusion

Adaptive cognitive training may enhance attentional engagement and inhibitory control in breast cancer survivors. Large-scale study is needed to confirm these effects and refine eye-tracking applications for CRCI assessment.

Implications for Cancer Survivors

Tablet-based cognitive training targeting cognitive control with adaptive difficulty levels may ameliorate CRCI among breast cancer survivors.